Paediatric autoimmune liver disease

Archives of Disease in Childhood

Volumn 98, Issue 12, 2013, Pages 1012-1017

  Mieli Vergani, Giorgina ^a   Vergani, Diego ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; BILIRUBIN; BUDESONIDE; CYCLOSPORIN A; GAMMA GLUTAMYLTRANSFERASE; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVER ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; PREDNISONE; TACROLIMUS; URSODEOXYCHOLIC ACID;

ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LIVER DISEASE; AUTOIMMUNE SCLEROSING CHOLANGITIS; BILE DUCT DISEASE; BILIRUBIN BLOOD LEVEL; CHILDHOOD DISEASE; CHOLANGIOGRAPHY; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FULMINANT HEPATIC FAILURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HYPOALBUMINEMIA; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAINTENANCE DRUG DOSE; MONOTHERAPY; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; RECURRENCE RISK; RECURRENT DISEASE; REMISSION; REVIEW; SCLEROSING CHOLANGITIS; SCORING SYSTEM; SIGMOIDOSCOPY; TREATMENT DURATION;

HEPATOLOGY; IMMUNOLOGY;

CHILD; CHOLANGITIS, SCLEROSING; DISEASE PROGRESSION; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER; MALE; TREATMENT OUTCOME;

EID: 84888642128     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-303848     Document Type: Review

References (59)

1. Liberal R, Longhi MS, Mieli-Vergani G, et al. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011;25:653-64.
2. Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol 2011;8:320-9.
3. Vergani D, Alvarez F, Bianchi FB, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004;41:677-83.
4. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-7.
5. Oettinger R, Brunnberg A, Gerner P, et al. Clinical features and biochemical data of Caucasian children at diagnosis of autoimmune hepatitis. J Autoimmun 2005;24:79-84.
6. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35:658-64.
7. Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children: what is different from adult AIH? Semin Liver Dis 2009;29:297-306.
8. Ahonen P, Myllarniemi S, Sipila I, et al. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990;322:1829-36.
9. Mieli-Vergani G, Vergani D. Autoimmune liver diseases in children - what is different from adulthood? Best Pract Res Clin Gastroenterol 2011;25:783-95.
10. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-53.
11. Debray D, Pariente D, Urvoas E, et al . Sclerosing cholangitis in children. J Pediatr 1994;124:49-56.
12. Wilschanski M, Chait P, Wade JA, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology 1995;22:1415-22.
13. Feldstein AE, Perrault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210-17.
14. Miloh T, Arnon R, Shneider B, et al. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009;7:239-45.
15. Baker AJ, Portmann B, Westaby D, et al. Neonatal sclerosing cholangitis in two siblings: a category of progressive intrahepatic cholestasis. J Ped Gastroenterol Nutr 1993;17:317-22.
16. Jacquemin E, De Vree JM, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001;120:1448-58.
17. Ziol M, Barbu V, Rosmorduc O, et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 2008;135:131-41.
18. Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut 2004;53:599-608.
19. Donaldson PT. Genetics of autoimmune and viral liver diseases; understanding the issues. J Hepatol 2004;41:327-32.
20. Ma Y, Bogdanos DP, Hussain MJ, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006;130:868-82.
21. Fainboim L, Canero Velasco MC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001;33:1512-17.
22. Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30:1374-80.
23. Vergani D, Wells L, Larcher VF, et al. Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis. Lancet 1985;2:294-8.
24. Underhill JA, Ma Y, Bogdanos DP, et al. Different immunogenetic background in autoimmune hepatitis type 1, type 2 and autoimmune sclerosing cholangitis. J Hepatol 2002;36:S156 (abstract).
25. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
26. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
27. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-76.
28. Vergani D, Mieli-Vergani G. Pharmacological management of autoimmune hepatitis. Expert Opin Pharmacother 2011;12:607-13.
29. Ferreira AR, Roquete ML, Toppa NH, et al. Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2008;46:65-70.
30. Kerkar N, Annunziato RA, Foley L, et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006;43:629-34.
31. Samaroo B, Samyn M, Buchanan C, et al. Long-term daily oral treatment with prednisolone in children with autoimmune liver disease does not affect final adult height. Hepatology 2006;44:438 (abstract).
32. Ferreira AR, Roquete ML, Penna FJ, et al. Type 1 autoimmune hepatitis in children and adolescents: assessment of immunosuppressive treatment withdrawal. J Pediatr (Rio J) 2005;81:343-8.
33. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-213.
34. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
35. Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008;7:319-33.
36. Banerjee S, Rahhal R, Bishop WP. Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J Ped Gastroenterol Nutr 2006;43:353-6.
37. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7.
38. Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010;139:1198-206.
39. Woynarowski M, Nemeth A, Baruch Y, et al. Budesonide vs prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents. J Pediatr 2013 Jun 27. pii: S0022-3476(13)00658-6. doi: 10.1016/j.jpeds.2013.05.042. [Epub ahead of print].
40. Mieli-Vergani G, Vergani D. Budesonide for juvenile autoimmune hepatitis Not yet. J Pediatr 2013 Aug 8. pii: S0022-3476(13)00823-8. doi: 10.1016/j.jpeds.2013.06.064. [Epub ahead of print].
41. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35:7-13.
42. Aw MM, Dhawan A, Samyn M, et al. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009;51:156-60.
43. Gregorio GV, McFarlane B, Bracken P, et al. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002;35:515-19.
44. Scalori AHM, Hadzic N, Vergani D, et al. Outcome and survival in childhood onset autoimmune sclerosing cholangitis and autoimmune hepatitis: a 13 years follow-up study. Hepatology 2007;46:555 (abstract).
45. Liberal R, Longhi MS, Grant CR, et al. Autoimmune hepatitis after liver transplantation. Clin Gastroenterol Hepatol 2012;10:346-53.
46. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351:409-13.
47. Vergani D, Mieli-Vergani G. Autoimmunity after liver transplantation. Hepatology 2002;36:271-6.
48. Mieli-Vergani G, Vergani D. De novo autoimmune hepatitis after liver transplantation. J Hepatol 2004;40:3-7.
49. Cho JM, Kim KM, Oh SH, et al. De novo autoimmune hepatitis in Korean children after liver transplantation: a single institution's experience. Transplant Proc 2011;43:2394-6.
50. Venick RS, McDiarmid SV, Farmer DG, et al. Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis. Am J Transpl 2007;7:955-63.
51. Evans HM, Kelly DA, McKiernan PJ, et al. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006;43:1109-17.
52. Kerkar N, Dugan C, Rumbo C, et al. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transpl 2005;5:1085-9.
53. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001;21:225-32.
54. Sakaguchi S, Sakaguchi N. Role of genetic factors in organ-specific autoimmune diseases induced by manipulating the thymus or T cells, and not self-antigens. Rev Immunogenet 2000;2:147-53.
55. Gao E, Lo D, Cheney R, et al. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988;336:176-9.
56. Bucy PB, Yan Xu X, Li J, et al. Cyclosporin A-induced autoimmune disease in mice. J Iimmunol 1993;151:1039-50.
57. Wu DY, Goldschneider I. Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. J Immunol 1999;162:6926-33.
58. Damoiseaux JG, van Breda Vriesman PJ. Cyclosporin A-induced autoimmunity: the result of defective de novo T-cell development. Folia Biol 1998;44:1-9.
59. Liberal R, Grant CR, Mieli-Vergani G, et al. Autoimmune hepatitis: a comprehensive review. J Autoimmunity 2013;41:126-39.